On August 14, 2024, Nikita Shah, Executive Vice President of Amneal Pharmaceuticals Inc (AMRX, Financial), sold 100,000 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 291,666 shares of Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc, a company engaged in the development, manufacture, and distribution of generic and specialty pharmaceutical products, has seen a notable insider transaction trend. Over the past year, there have been no insider purchases but three insider sales, including the recent transaction by the insider.
Shares of Amneal Pharmaceuticals Inc were priced at $7.75 on the day of the sale. The company currently holds a market cap of approximately $2.49 billion. According to the GF Value, the intrinsic value estimate for the stock is $2.94, indicating a price-to-GF-Value ratio of 2.64, which suggests that the stock is Significantly Overvalued.
The GF Value is determined by considering historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from analysts.
This sale by the insider might be of interest to current and potential investors, providing insight into insider confidence and stock valuation perceptions at Amneal Pharmaceuticals Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
